Single nucleotide polymorphisms of the tcdC gene and presence of the binary toxin gene predict recurrent episodes of Clostridium difficile infection

Annals of Surgery

Volumn 260, Issue 2, 2014, Pages 299-304

  Stewart, David B ^a   Berg, Arthur S ^a   Hegarty, John P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Binary toxin; C difficile; Recurrence; Single nucleotide polymorphism; TcdC

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL TOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; PROTEIN TCDC; QUINOLONE; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR; BACTERIAL PROTEIN; ENTEROTOXIN; GENETIC MARKER; REPRESSOR PROTEIN; TCDC PROTEIN, CLOSTRIDIUM DIFFICILE;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; FEMALE; GENE DELETION; GENE MUTATION; GENOTYPE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTPATIENT; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RIBOTYPING; SINGLE NUCLEOTIDE POLYMORPHISM; CLOSTRIDIUM INFECTION; FECES; GENETIC MARKER; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE;

AGED; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; FECES; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RECURRENCE; REPRESSOR PROTEINS; RIBOTYPING; VIRULENCE FACTORS;

EID: 84905584223     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000469     Document Type: Article

References (25)

1. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43-50.
2. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
3. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;55:S77-S87.
4. Wenisch JM, Schmid D, Kuo HW, et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis. 2012;31:1923-1930.
5. Kwok CS, Arthur AK, Anibueze Ci, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. AmJGastroenterol. 2012;107:1011-1019.
6. Janarthanan S, Ditah I, Alder DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107:1001-1010.
7. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol. 2012;46:397-400.
8. Leonard AD, Ho KM, Flexman J. Proton pump inhibitors and diarrhea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J. 2012;42:591-594.
9. Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg. 2013;17:118-125.
10. Geric B, Johnson S, Gerding DN, et al. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol. 2003;41:5227-5232.
11. Stubbs S, Rupnik M, Gibert M, et al. Production of actin specific ADPribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett. 2000;186:307-312.
12. Barth H, Aktories K, Popoff MR, et al. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus mechanism of ADP ribosylating toxins. FEBS J. 2006;273:4579-4593.
13. Davies AH, Roberts AK, Shone CC, et al. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem J. 2011;436:517-526.
14. Dupuy B, Govind R, Antunes A, et al. Clostridium difficile synthesis is negatively regulated by TcdC. J Med Microbiol. 2008;57:685-689.
15. Braun V, Hundsberger T, Leukel P, et al. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene. 1996;181:29-38.
16. Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol. 2007;64:1274-1288.
17. Carter GP, Douce GR, Govind R, et al. The anti-sigma factor tcdC modulates hypervirulence in an epidemic B1/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 2011;10:e1002317.
18. Curry SR, Marsh JW, Muto CA, et al. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol. 2007;45:215-221.
19. Rupnik M, Avesani V, Janc M, et al. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol. 1998;36:2240-2247.
20. Stubbs SL, Brazier JS, O'Neill GL, et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol. 1999;37:461-463.
21. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol. 2002;40:3470-3475.
22. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
23. Soehn F, Wagenknecht-Wiesner A, Leukel P, et al. Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864: implications for transcription, expression, and enzymatic activity of toxins A and B. Mol Gen Genet. 1998;258:222-232.
24. Karlsson S, Burman LG, Akerlund T. Induction of toxins in Clostridium difficile is associated with dramatic changes in its metabolism. Microbiology. 2008;154:3430-3436.
25. Oezquen N, Power TD, Urvil P, et al. Clostridal toxins: sensing a target in a hostile gut environment. Gut Microbes. 2012;3:35-41.